A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
- 28 June 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (7), 699-731
- https://doi.org/10.1634/theoncologist.2010-0025
Abstract
Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent developments in gene sequencing and molecular diagnostics have led to high expectations for the identification of molecular markers to be used in optimized and tailored treatment regimens. However, many of the published data on molecular biomarkers are contradictory in their findings and the current reality is that no molecular marker, other than the KRAS gene in the case of epidermal growth factor receptor (EGFR)- targeted therapy for metastatic disease, has made it into clinical practice. Many markers investigated suffer from technical shortcomings, resulting from lack of quantitative techniques to capture the impact of the molecular alteration. This understanding has recently led to the more comprehensive approaches of global gene expression profiling or genome-wide analysis to determine prognostic and predictive signatures in tumors. In this review, an update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability, epidermal growth factor receptor, KRAS, BRAF, CpG island methylator phenotype, cytotoxic T lymphocytes, forkhead box P3–positive T cells, receptor for hyaluronic acid–mediated motility, phosphatase and tensin homolog, and T-cell originated protein kinase, in patients with CRC is provided.Keywords
This publication has 161 references indexed in Scilit:
- Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancerBritish Journal of Surgery, 2009
- Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-β pathwayEuropean Journal Of Cancer, 2007
- Molecular prognostic markers in resectable colorectal liver metastases: A systematic reviewEuropean Journal Of Cancer, 2006
- Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancerLaboratory Investigation, 2006
- A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosisEuropean Journal Of Cancer, 2005
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001
- Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerThe Lancet, 2000
- C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomasEuropean Journal Of Cancer, 1996
- The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survivalInternational Journal of Cancer, 1994